(NASDAQ: MGTX) Meiragtx Holdings's forecast annual revenue growth rate of 11.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Meiragtx Holdings's revenue in 2026 is $81,391,000.On average, 9 Wall Street analysts forecast MGTX's revenue for 2026 to be $10,783,467,082, with the lowest MGTX revenue forecast at $478,903,221, and the highest MGTX revenue forecast at $15,958,553,928. On average, 7 Wall Street analysts forecast MGTX's revenue for 2027 to be $11,198,027,864, with the lowest MGTX revenue forecast at $5,784,385,315, and the highest MGTX revenue forecast at $21,037,534,346.
In 2028, MGTX is forecast to generate $8,564,874,610 in revenue, with the lowest revenue forecast at $3,055,369,971 and the highest revenue forecast at $12,143,617,387.